Editorial

# Erroneous uses of NSAIDs in Patients with COVID-19, Dengue, and Chikungunya

Abdul Kader Mohiuddin \*

Alumni, Faculty of Pharmacy, Dhaka University.

\*Corresponding Author: Abdul Kader Mohiuddin, Alumni, Faculty of Pharmacy, Dhaka University.

## Received date: November 26, 2022; Accepted date: January 30, 2023; Published date: February 09, 2023

**Citation:** Abdul Kader Mohiuddin (2023), Erroneous uses of NSAIDs in patients with COVID-19, Dengue, and Chikungunya. *J, Clinical Case Reports and Studies*, 4(2); DOI:10.31579/2690-8808/0159

**Copyright:** © 2023 Abdul Kader Mohiuddin, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Abstract

The article shows that the current level of physiology does not disclose the biological mechanisms of the organism transition from one range to adapt to a higher with an increase in the regular forces of the stimulus above sub-extreme. A new trend in the physiology of adaptation - proqredient adaptation, explains the mechanism of increasing the tolerance of the organism, with dependence on psychoactive substances (PAS). It is scientifically proved, that dependences of the organism on PAS not the disease, and the states like proqredient (progressive) adaptation.

**Key Words:** pain management; cautions with SSRIs; hypertensive patients with viral fever; misuse of NSAIDs; NSAIDs in kidney-compromised patients

## **Abbreviations:**

Angiotensin-converting enzyme (ACE) inhibitors Angiotensin II receptor type 2 (AT-2) blockers Adverse Drug Reaction (ADR) Non-steroidal anti-inflammatory drugs (NSAIDs) US Centers for Disease Control and Prevention (CDC) World Health Organization (WHO) Introduction

Introduction

NSAIDs are considered the mainstay of current therapies for viral arthropathies, albeit they frequently only offer partial relief. Numerous studies have documented widespread abuse of NSAIDs among Covid-19, Dengue, and Chikungunya patients. NSAIDs can be used to treat severe arthralgia, however the WHO advises against doing so in suspected Chikungunya patients until it has been determined that they do not have dengue. Acetaminophen is recommended by consensus guidelines for treating Dengue fever from the WHO and CDC, although NSAIDs are contraindicated due to a possible increase in bleeding risk, which could result in thrombocytopenia as a side effect.

Maintaining the body hydration level is more crucial than bringing down the temperature with painkillers, especially in Dengue or Covid-19 patients. In children, using too much paracetamol syrup or suppositories might irritate the stomach, preventing proper digestion, leading to vomiting, and even necessitating hospitalization. With very few exceptions, the majority of hospitalizations or ICU admissions among those individuals might be

avoided by just avoiding dehydration at home with saline and fruit juice or by simply drinking more water.

At least 165,000 fatalities, 650,000 hospitalizations, and 30% of ADR related hospital admissions worldwide are attributable to NSAIDs, mostly as a result of bleeding, heart attacks, strokes, and renal impairment [1, 2]. Additionally, overusing this class of medications can result in kidney damage, and kidney patients may experience its side effects at a 3–4 times higher rate [3]. This is particularly crucial because clinical experience and publications have shown that kidney involvement was found up to 75% of the patients with COVID-19 [4].

Hypertension or cardiac involvements was the most common pre-existing comorbidities in fetal cases of Covid-19 and Chikungunya patients [5, 6]. NSAIDs have numerous potentially deleterious effects on immune function and they interact with many drugs which are used in patients with cardio- or cerebrovascular disorders: They attenuate the effects of diuretics, betablockers, ACE inhibitors and AT-2 blockers, thus leading to uncontrolled hypertension or aggravation of heart failure [7].

Patients with Covid-19 who have trouble sleeping make up 40% of the population. The use of benzodiazepines is contraindicated with various antiviral medications, increases the risk of delirium and respiratory depression. However, physicians should recognize that concurrent use of Selective Serotonin Reuptake Inhibitors (SSRIs) and NSAIDs was related with a 75% increased risk of upper GI bleeding and should advise patients appropriately if they choose to utilize SSRIs for the same [8]. This is particularly concerning because NSAIDs are frequently taken daily or

#### J. Clinical Case Reports and Studies

#### Copy rights @ Abdul Kader Mohiuddin. et all

sometimes many times per day, and SSRIs are typically prescribed for daily usage.

Finally, it is recommended that pain modulation therapy, especially with NSAIDs, is important for the management of outpatients with early symptoms of COVID-19. Co-administration of NSAIDs with low-dose systemic corticosteroids has been advised to reduce pain and improve quality of life in patients with Chikungunya, only if the benefits outweigh the risks. In both of these cases, other comorbid situations should be carefully considered. NSAIDs are contra-indicated in Dengue fever. In addition to recommending daily follow-up, Dengue patients who are being followed as outpatients must be counseled on appropriate home care and on attending to warning signs warranting an earlier return to the clinic for re-evaluation. Along with tepid sponging, acetaminophen is advised for fever relief.

**Declaration:** The study does not promote use of steroid painkillers in any forms in any of the stated viral conditions

### Financial Disclosure or Funding: N/A

**Conflict of Interest**: The author declares that he has no competing interests. **Informed Consent**: N/A

#### References

 Lucas GNC, Leitão ACC, Alencar RL, Xavier RMF, Daher EF, Silva Junior GBD. (2019). Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs. J Bras Nefrol. 41(1):124-130.

- Davis, Abigail, and John Robson. "The Dangers of Nsaids: Look Both Ways." British Journal of General Practice, vol. 66, no. 645, 2016, pp. 172-173.
- 3. Mohiuddin, Abdul Kader. (2022). "Medication Adherence: Fact or Fictions?" Open Journal of Pharmaceutical Science and Research, no. 4, 24 Nov., pp. 6-10.
- Esposito, Pasquale et al. (2022). "Changes of Acute Kidney Injury Epidemiology during the COVID-19 Pandemic: A Retrospective Cohort Study." Journal of clinical medicine vol.
- Peng, Mei et al. (2021). "Role of Hypertension on the Severity of COVID-19: A Review." Journal of cardiovascular pharmacology. 648-655.
- Sharp TM, Keating MK, Shieh WJ, Bhatnagar J, Bollweg BC, Levine R, Blau DM, Torres JV, Rivera A, Perez-Padilla J, Munoz-Jordan J, Sanabria D, Fischer M, Rivera Garcia B, Tomashek KM, Zaki SR. (2021). Clinical Characteristics, Histopathology, and Tissue Immunolocalization of Chikungunya Virus Antigen in Fatal Cases. Clin Infect Dis. Jul 15;73(2):345-354.
- Stöllberger C, Finsterer J. (2003). Nonsteroidal antiinflammatory drugs in patients with cardio- or cerebrovascular disorders. Z Kardiol. 92(9):721-729.
- Alam SM, Qasswal M, Ahsan MJ, Walters RW, Chandra S. (2022). Selective serotonin reuptake inhibitors increase risk of upper gastrointestinal bleeding when used with NSAIDs: a systemic review and meta-analysis. Sci Rep. 12(1):14452.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here: Submit Manuscript

DOI:10.31579/2690-8808/159

#### Ready to submit your research? Choose Auctores and benefit from:

- > fast, convenient online submission
- > rigorous peer review by experienced research in your field
- > rapid publication on acceptance
- > authors retain copyrights
- > unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more <u>https://auctoresonline.org/journals/journal-of-clinical-case-reports-and-studies</u>